Our Pricing

Wegovy Stock Available - Order Now

Published on: June 03, 2026

Finding wegovy stock available uk pharmacies has been challenging following nationwide shortages, but Cured Pharmacy maintains consistent supply of genuine UK-licensed Wegovy pens from £79.00. Our UK-registered clinical team can assess your suitability and arrange discreet next-day delivery, subject to prescriber approval.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related health conditions [1]. Semaglutide mimics the action of glucagon-like peptide-1, a natural hormone that regulates appetite and food intake by acting on areas of the brain involved in hunger control.

In the landmark STEP 1 trial, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. The medication works by slowing gastric emptying, reducing hunger signals, and increasing feelings of fullness after meals, helping patients adhere to reduced-calorie diets more effectively.

Clinical trials demonstrated that approximately two-thirds of patients on Wegovy lost at least 10% of their body weight, with one-third losing 20% or more when combined with lifestyle modifications [1]. These results represent some of the most significant weight loss outcomes seen with pharmacological intervention in obesity management.

Wegovy Dosing Schedule and Administration

Wegovy follows a gradual dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising efficacy. Treatment begins with a 0.25 mg once-weekly injection for the first month, increasing monthly through 0.5 mg, 1 mg, and 1.7 mg doses before reaching the maintenance dose of 2.4 mg [2].

Each pre-filled pen delivers a single dose administered subcutaneously into the abdomen, thigh, or upper arm. Patients typically inject on the same day each week, with the flexibility to change the day if needed, provided at least two days pass between doses. The entire escalation process takes approximately 16 to 20 weeks, allowing your body to adjust gradually to the medication.

Our superintendent pharmacist Tarun Kumar and the clinical team at Cured Pharmacy provide comprehensive injection technique guidance with every prescription. Proper injection site rotation and technique are essential for optimal absorption and minimising injection site reactions.

Managing Side Effects During Dose Escalation

Gastrointestinal symptoms including nausea, diarrhoea, and constipation are the most commonly reported side effects, typically occurring during dose increases and diminishing over time [2]. Eating smaller, more frequent meals and avoiding high-fat foods can help manage these symptoms. If side effects persist, your prescriber may recommend staying at your current dose for an additional month before escalating further.

Wegovy Stock Availability and UK Supply

The UK experienced significant Wegovy supply constraints throughout 2023 and early 2024 due to unprecedented global demand following regulatory approvals and widespread media coverage of GLP-1 medications. Novo Nordisk, the manufacturer, implemented allocation systems prioritising existing patients to prevent treatment interruptions.

At Cured Pharmacy, we maintain direct relationships with UK-licensed wholesalers and have secured consistent wegovy stock available uk for both new and continuing patients. Our transparent pricing model means you see the exact cost—from £79.00—before completing your clinical assessment, with no hidden fees or subscription requirements.

All Wegovy pens dispensed through our pharmacy are genuine UK-licensed medicines sourced through regulated pharmaceutical supply chains. We never source from grey market suppliers or international jurisdictions, ensuring every pen meets MHRA quality and safety standards. Stock levels are updated in real-time, and our team contacts patients immediately if any supply issues arise.

Clinical Eligibility and Prescriber Assessment

Wegovy is licensed for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. The medication is not licensed for cosmetic weight loss or for individuals within a healthy BMI range.

During your online consultation, a UK-registered prescriber reviews your medical history, current medications, and weight loss goals to determine suitability. Certain conditions preclude Wegovy use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy [3].

The assessment typically takes under three minutes to complete and includes questions about previous weight loss attempts, eating patterns, and any contraindications. If Wegovy is not suitable, our prescribers may recommend alternative treatments or suggest consulting your NHS GP for additional support. All prescription decisions are made independently by UK-registered clinicians in accordance with GMC and GPhC guidelines.

Monitoring and Follow-Up Requirements

NICE guidance recommends reviewing weight loss progress after 12 weeks of treatment at the maintenance dose. Patients should achieve at least 5% body weight reduction to continue therapy, as this threshold indicates clinical benefit and likelihood of further weight loss [4]. Our clinical team conducts regular medication reviews to assess progress, manage any side effects, and adjust treatment plans as needed.

Wegovy vs Other Weight Loss Medications

Several GLP-1 receptor agonists are now licensed for weight management in the UK, each with distinct characteristics. Wegovy contains semaglutide administered once weekly, whilst Saxenda contains liraglutide requiring daily injections. Newer dual-action medications targeting both GIP and GLP-1 receptors have shown even greater weight loss in clinical trials, though individual response varies significantly.

Head-to-head trials comparing semaglutide with liraglutide demonstrated superior weight loss with semaglutide, attributed to its longer half-life and higher receptor binding affinity [5]. However, medication selection depends on individual factors including BMI, comorbidities, previous treatment response, injection frequency preference, and cost considerations.

Your prescriber considers multiple factors when recommending a specific treatment, including your weight loss target, budget, tolerance for injections, and any previous experience with GLP-1 medications. Some patients prefer starting with lower-cost options before escalating to more potent treatments, whilst others prioritise maximum efficacy from the outset.

Ordering Wegovy from Cured Pharmacy

Our streamlined process ensures you receive your medication quickly and discreetly. After completing the free online consultation, a UK prescriber reviews your assessment within hours. Once approved, your prescription is dispensed by our GPhC-registered pharmacy (9012511) and dispatched in plain, unmarked packaging via Royal Mail or courier service.

We offer flexible payment options and transparent pricing with no subscription lock-ins or recurring charges. You order only when you need your next supply, with automated reminders available if desired. Our customer care team is available on (+44) 116 4646009 during business hours to answer questions about your treatment, delivery, or clinical concerns.

All wegovy stock available uk through Cured Pharmacy comes with comprehensive patient information leaflets, injection technique guides, and access to our clinical support team. We maintain the lowest prices guaranteed across UK online pharmacies whilst never compromising on medication authenticity or clinical standards. Your treatment journey is supported from initial consultation through ongoing medication reviews, ensuring safe and effective weight management.

Discreet Delivery and Packaging

Every order ships in 100% discreet packaging with no external markings indicating pharmacy or medication contents. Wegovy requires refrigerated storage between 2°C and 8°C, and we use temperature-controlled packaging with ice packs to maintain cold chain integrity during transit. Upon delivery, transfer your pens to a refrigerator immediately and never freeze them.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Public Assessment Report. GOV.UK. https://www.gov.uk/government/publications/wegovy-24-mg-solution-for-injection-in-pre-filled-pen [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. NICE Technology Appraisal Guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. O'Neil, P. M., et al. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet, 392(10148), 637–649. https://doi.org/10.1016/S0140-6736(18)31773-2 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.